Identification
NameSatraplatin
Accession NumberDB04996
TypeSmall Molecule
GroupsInvestigational
Description

Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies.

Structure
Thumb
SynonymsNot Available
External IDs BMS-182751 / BMY-45594 / JM-216
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII8D7B37T28G
CAS number129580-63-8
WeightAverage: 500.283
Monoisotopic: 499.060437065
Chemical FormulaC10H22Cl2N2O4Pt
InChI KeyCKNPWBAXEKSCRG-UHFFFAOYSA-J
InChI
InChI=1S/C6H13N.2C2H4O2.2ClH.H3N.Pt/c7-6-4-2-1-3-5-6;2*1-2(3)4;;;;/h6H,1-5,7H2;2*1H3,(H,3,4);2*1H;1H3;/q;;;;;;+4/p-4
IUPAC Name
platinum(4+) ion cyclohexanamine diacetate amine dichloride
SMILES
N.[Cl-].[Cl-].[Pt+4].CC([O-])=O.CC([O-])=O.NC1CCCCC1
Pharmacology
Indication

Investigated for use/treatment in lung cancer, prostate cancer, and solid tumors.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

The drug has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.

TargetKindPharmacological actionActionsOrganismUniProt ID
DNANucleotideunknownNot AvailableHumannot applicabledetails
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Satraplatin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Satraplatin.Approved, Investigational
CabazitaxelSatraplatin may increase the myelosuppressive activities of Cabazitaxel.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Satraplatin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Satraplatin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Satraplatin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Satraplatin.Approved
DocetaxelSatraplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
FosphenytoinThe serum concentration of Fosphenytoin can be decreased when it is combined with Satraplatin.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Satraplatin.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Satraplatin.Approved
PaclitaxelSatraplatin may increase the myelosuppressive activities of Paclitaxel.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Satraplatin.Approved, Vet Approved
TopotecanThe risk or severity of adverse effects can be increased when Satraplatin is combined with Topotecan.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Satraplatin.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL01XA04 — Satraplatin
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentMetastatic Brain Tumors / Neoplasms, Brain / Tumors, Solid1
1TerminatedTreatmentMalignancies1
1TerminatedTreatmentProstate Cancer / Tumors1
1TerminatedTreatmentTumors1
1, 2TerminatedTreatmentLung Cancers / Non-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentPolymorphism, Genetic / Prostate Cancer1
2CompletedTreatmentProstate Cancer1
3CompletedTreatmentHormone Refractory Prostate Cancer / Prostate Cancer1
3TerminatedTreatmentProstate Cancer1
Not AvailableCompletedTreatmentProstate Cancer1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility0.4 mg/ml at pH 1-7.5Not Available
Predicted Properties
PropertyValueSource
logP1.17ChemAxon
pKa (Strongest Basic)10.45ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area26.02 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity30.93 m3·mol-1ChemAxon
Polarizability12.44 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6502
Blood Brain Barrier+0.7841
Caco-2 permeable-0.6468
P-glycoprotein substrateNon-substrate0.6858
P-glycoprotein inhibitor INon-inhibitor0.9881
P-glycoprotein inhibitor IINon-inhibitor0.9863
Renal organic cation transporterNon-inhibitor0.9154
CYP450 2C9 substrateNon-substrate0.8261
CYP450 2D6 substrateNon-substrate0.8462
CYP450 3A4 substrateNon-substrate0.6351
CYP450 1A2 substrateNon-inhibitor0.8764
CYP450 2C9 inhibitorNon-inhibitor0.905
CYP450 2D6 inhibitorNon-inhibitor0.9427
CYP450 2C19 inhibitorNon-inhibitor0.866
CYP450 3A4 inhibitorNon-inhibitor0.8794
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9813
Ames testNon AMES toxic0.6304
CarcinogenicityNon-carcinogens0.811
BiodegradationReady biodegradable0.6692
Rat acute toxicity2.4085 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9732
hERG inhibition (predictor II)Non-inhibitor0.9639
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
ClassificationNot classified

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
unknown
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
Drug created on October 21, 2007 16:23 / Updated on September 01, 2017 11:23